van Wetering Carel R, van Nooten Floortje E, Mol Stijn J M, Hoogendoorn Martine, Rutten-Van Mölken Maureen P M H, Schols Annemie M
Department of Physiotherapy, Máxima Medical Centre,Veldhoven, The Netherlands.
Int J Chron Obstruct Pulmon Dis. 2008;3(3):443-51. doi: 10.2147/copd.s2588.
In contrast with the frequency distribution of chronic obstructive pulmonary disease (COPD) stages in the population, in which the majority of the patients is classified as GOLD 2, much less information is available on the prevalence and implications of systemic manifestations in less severe patients relative to GOLD 3 and 4.
To characterize local and systemic impairment in relation to disease burden in a group of GOLD 2 COPD patients (n = 127, forced expiratory volume in one second (SD): 67 (11)% pred) that were eligible for the Interdisciplinary Community-based COPD management (INTERCOM) trial.
Patients were included for this lifestyle program based on a peak exercise capacity (Wmax) < 70% of predicted. Metabolic and ventilatory response to incremental cycle ergometry, 6 minute walking distance (6MWD), constant work rate test (CWR), lung function, maximal inspiratory pressure (Pimax), quadriceps force (QF), quadriceps average power (QP) (isokinetic dynamometry), handgrip force (HGF) and body composition were measured. Quality of life (QoL) was assessed by the St. George's Respiratory Questionnaire (SGRQ) and dyspnea by the modified Medical Research Council (MRC) dyspnea scale. Exacerbations and COPD-associated hospital admissions in 12 months prior to the start of the study were recorded. Burden of disease was defined in terms of exercise capacity, QoL, hospitalization, and exacerbation frequency. GOLD 2 patients were compared with reference values and with GOLD 3 patients who were also included in the trial.
HGF (77.7 (18.8) % pred) and Pimax (67.1 (22.5)% pred) were impaired in GOLD 2, while QF (93.5 (22.5)% pred) was only modestly decreased. Depletion of FFM was present in 15% of weight stable GOLD 2 patients while only 2% had experienced recent involuntary weight loss. In contrast to Wmax, submaximal exercise capacity, muscle function, and body composition were not significantly different between GOLD 2 and 3 subgroups. Body mass index and fat-free mass index were significantly lower in smokers compared to ex-smokers. In multivariate analysis, QF and diffusing capacity (DLco) were independently associated with Wmax and 6 MWD in GOLD 2 while only 6 MWD was identified as an independent determinant of health-related QoL. HGF was an independent predictor of hospitalization.
This study shows that also in patients with moderate COPD, eligible for a lifestyle program based on a decreased exercise capacity, systemic impairment is an important determinant of disease burden and that smoking affects body composition.
与慢性阻塞性肺疾病(COPD)患者在人群中的阶段频率分布情况不同,其中大多数患者被归类为GOLD 2期,而关于病情较轻(相对于GOLD 3和4期)的患者全身表现的患病率及影响的信息要少得多。
对一组符合跨学科社区COPD管理(INTERCOM)试验条件的GOLD 2期COPD患者(n = 127,一秒用力呼气量(标准差):67(11)%预计值)的局部和全身损害与疾病负担的关系进行特征描述。
基于峰值运动能力(Wmax)<预计值的70%,将患者纳入该生活方式项目。测量递增式自行车测力计运动时的代谢和通气反应、6分钟步行距离(6MWD)、恒定工作率测试(CWR)、肺功能、最大吸气压力(Pimax)、股四头肌力量(QF)、股四头肌平均功率(QP)(等速测力法)、握力(HGF)和身体成分。采用圣乔治呼吸问卷(SGRQ)评估生活质量(QoL),采用改良的医学研究理事会(MRC)呼吸困难量表评估呼吸困难情况。记录研究开始前12个月内的急性加重次数和COPD相关住院情况。根据运动能力、QoL、住院情况和急性加重频率来定义疾病负担。将GOLD 2期患者与参考值以及也纳入该试验的GOLD 3期患者进行比较。
GOLD 2期患者的HGF(77.7(18.8)%预计值)和Pimax(67.1(22.5)%预计值)受损,而QF(93.5(22.5)%预计值)仅略有下降。15%体重稳定的GOLD 2期患者存在去脂体重减少,而只有2%近期有非自愿体重减轻。与Wmax不同,GOLD 2期和3期亚组之间的次最大运动能力、肌肉功能和身体成分无显著差异。吸烟者的体重指数和去脂体重指数显著低于已戒烟者。在多变量分析中,GOLD 2期患者的QF和弥散能力(DLco)与Wmax和6MWD独立相关,而只有6MWD被确定为健康相关QoL的独立决定因素。HGF是住院的独立预测因素。
本研究表明,对于符合基于运动能力下降的生活方式项目条件的中度COPD患者,全身损害也是疾病负担的重要决定因素,且吸烟会影响身体成分。